A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

NCT00168298 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

668

Enrollment

INDUSTRY

Sponsor class

Conditions

Macular Edema
Retinal Vein Occlusion

Interventions

DRUG: 700 µg Dexamethasone
DRUG: 350 µg Dexamethasone
OTHER: Sham Injection

Sponsor

Allergan